Drugs
As of the edition of 20 October 2026, this index lists 10 pages.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
10 pages
- Atezolizumab Marketed
- Bevacizumab Marketed
- Durvalumab Marketed
- Ipilimumab Marketed
- Lenalidomide Marketed
- Nivolumab Marketed
- Pembrolizumab Marketed
- Rituximab Marketed
- Tocilizumab Marketed
- Venetoclax Marketed